A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

计划入组 120 人 · 首次发布于 2006 年 11 月 3 日

Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

计划入组 300 人 · 首次发布于 2005 年 9 月 20 日

A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)

计划入组 16 人 · 首次发布于 2015 年 4 月 22 日

P38 MAP kinase inhibitors (steroid insensitive asthma)

Inhibitor of P38 Kinase

C₁₅H₁₄N₂

CT-P38

Exelixis, Inc.

United States

Inhibikase Therapeutics

United States

Regeneron Pharmaceuticals

United States

CervoMed's Neflamapimod Phase 2a Biomarker Data in nfvPPA Selected for Late-Breaking ISFTD Presentation

Poolbeg Pharma Secures European Patent for POLB 001 Targeting Severe Influenza and Cancer Immunotherapy Side Effects

Poolbeg Pharma's POLB 001 Takes Center Stage in £3.4 Million CRS Prevention Research Programme